Logo image of FREQ

FREQUENCY THERAPEUTICS INC (FREQ) Stock Fundamental Analysis

NASDAQ:FREQ - Nasdaq - US35803L1089 - Common Stock - Currency: USD

0.2996  +0.02 (+5.94%)

Fundamental Rating

2

FREQ gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 551 industry peers in the Biotechnology industry. The financial health of FREQ is average, but there are quite some concerns on its profitability. FREQ does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

FREQ had negative earnings in the past year.
FREQ had a negative operating cash flow in the past year.
In the past 5 years FREQ always reported negative net income.
In the past 5 years FREQ reported 4 times negative operating cash flow.
FREQ Yearly Net Income VS EBIT VS OCF VS FCFFREQ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 0 20M -20M -40M -60M -80M

1.2 Ratios

FREQ has a worse Return On Assets (-76.59%) than 70.30% of its industry peers.
FREQ's Return On Equity of -145.99% is on the low side compared to the rest of the industry. FREQ is outperformed by 68.48% of its industry peers.
Industry RankSector Rank
ROA -76.59%
ROE -145.99%
ROIC N/A
ROA(3y)-41%
ROA(5y)-34.99%
ROE(3y)-65.47%
ROE(5y)-52.09%
ROIC(3y)N/A
ROIC(5y)N/A
FREQ Yearly ROA, ROE, ROICFREQ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for FREQ so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FREQ Yearly Profit, Operating, Gross MarginsFREQ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 0 -200 -400 -600

More info and screens

5

2. Health

2.1 Basic Checks

FREQ does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for FREQ has been increased compared to 1 year ago.
FREQ has a worse debt/assets ratio than last year.
FREQ Yearly Shares OutstandingFREQ Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 10M 20M 30M
FREQ Yearly Total Debt VS Total AssetsFREQ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -5.79, we must say that FREQ is in the distress zone and has some risk of bankruptcy.
FREQ has a Altman-Z score of -5.79. This is in the lower half of the industry: FREQ underperforms 68.98% of its industry peers.
There is no outstanding debt for FREQ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.79
ROIC/WACCN/A
WACC9.02%
FREQ Yearly LT Debt VS Equity VS FCFFREQ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 3.14 indicates that FREQ has no problem at all paying its short term obligations.
The Current ratio of FREQ (3.14) is worse than 68.48% of its industry peers.
FREQ has a Quick Ratio of 3.14. This indicates that FREQ is financially healthy and has no problem in meeting its short term obligations.
FREQ's Quick ratio of 3.14 is on the low side compared to the rest of the industry. FREQ is outperformed by 67.66% of its industry peers.
Industry RankSector Rank
Current Ratio 3.14
Quick Ratio 3.14
FREQ Yearly Current Assets VS Current LiabilitesFREQ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

FREQ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.39%, which is quite good.
FREQ shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)13.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.91%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, FREQ will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.00% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y31.85%
EPS Next 2Y22.39%
EPS Next 3Y13.2%
EPS Next 5Y9%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
FREQ Yearly Revenue VS EstimatesFREQ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2028 2029 2030 50M 100M 150M 200M 250M
FREQ Yearly EPS VS EstimatesFREQ Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

FREQ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FREQ. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FREQ Price Earnings VS Forward Price EarningsFREQ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FREQ Per share dataFREQ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as FREQ's earnings are expected to grow with 13.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.39%
EPS Next 3Y13.2%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FREQ!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FREQUENCY THERAPEUTICS INC

NASDAQ:FREQ (11/3/2023, 8:00:00 PM)

0.2996

+0.02 (+5.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-02 2023-11-02/bmo
Earnings (Next)03-08 2024-03-08/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners6.57%
Ins Owner Change0%
Market Cap11.06M
Analysts43.33
Price Target0.51 (70.23%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.2%
Min EPS beat(2)-28.23%
Max EPS beat(2)23.84%
EPS beat(4)3
Avg EPS beat(4)3.01%
Min EPS beat(4)-28.23%
Max EPS beat(4)23.84%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-87.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-2.99%
EPS NY rev (3m)3.56%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.21
P/tB 0.21
EV/EBITDA N/A
EPS(TTM)-2.2
EYN/A
EPS(NY)-1.16
Fwd EYN/A
FCF(TTM)-1.49
FCFYN/A
OCF(TTM)-1.49
OCFYN/A
SpS0
BVpS1.44
TBVpS1.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -76.59%
ROE -145.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-41%
ROA(5y)-34.99%
ROE(3y)-65.47%
ROE(5y)-52.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.89%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.14
Quick Ratio 3.14
Altman-Z -5.79
F-Score2
WACC9.02%
ROIC/WACCN/A
Cap/Depr(3y)228.34%
Cap/Depr(5y)176.71%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.91%
EPS Next Y31.85%
EPS Next 2Y22.39%
EPS Next 3Y13.2%
EPS Next 5Y9%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year14.45%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y19.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.23%
OCF growth 3YN/A
OCF growth 5YN/A